Objectives: Fear of disease progression (FoP) in parental caregivers of minors with cystic fibrosis (CF) is associated with distress and adherence to treatment. Measures for FoP are available for adult patients and their partners, but so far not applicable for caregivers. We developed a caregiver form of the questionnaire to apply for parental caregivers and investigated its psychometric properties. Methods: Sixteen items were derived from the existing versions of the questionnaire and from interviews with clinical experts in family-oriented psychosocial care. Psychometric properties were tested in a sample of 50 caregivers (M = 38.4 years; SD = 6.72; 86% female) being interested to participate in a web-based psychotherapy for highly distressed caregivers of minors with CF. Internal consistency and convergent validity to other measures of distress (anxiety, depression) as well as divergent validity (parental quality of life) and sensitivity for change were investigated. Results: Internal consistency was indicated by Cronbach's a = 0.88, split-half reliability r = 0.82 and odd-even reliability r = 0.92. Moderate positive correlations with anxiety (r = 0.51; p < 0.01) and depression (r = 0.57; p < 0.01) were found, as well negative moderate correlations to quality of life (r = −0.54; p < 0.01). A subgroup of 23 participants receiving the web-based cognitive behavioural intervention showed a significant decrease of FoP-score (d = 1.11). Objectives: A major new development in CF treatment are drugs that target mutation class, so that potential benefits may not − at present − be available to all patients with CF. This may lead to CF being viewed differently by teams and families, as a number of conditions rather than one. This study explored the understanding of parents with young children with CF. Methods: A short survey asking about knowledge of mutation type and class and the potential importance of this on symptoms and treatment was circulated to parents of young children (<5 years) with CF attending the Leeds Regional Paediatric unit. Results: 22 parents completed the survey. Three knew both of their child's mutations, 16 knew one, 3 were unsure. 9 (32%) knew their child's mutation class. All knew that both parents were carriers of the CF gene. Most knew that mutation class had an impact on health and symptom severity in CF, though there was also confusion with around 1/3 of respondents unsure or believing it made no or little difference. 11 (64%) felt it might influence future treatment options, though 8 (36%) were unsure. Conclusion: Many parents are broadly aware that mutation class may be important in terms of severity of CF and future treatment, though many do not know their child's mutation type. There is still some uncertainty amongst parents about how their child's mutation types will affect what treatments are available for them in the future.
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Grandparental knowledge of cystic fibrosis treatment
Conclusion: Admission to hospital can be a difficult experience. Providing adequate information is essential in reducing parental stress, influencing how future experiences are appraised and managed. Effective physician-parent communication and opportunities to participate in care will improve parental satisfaction.
